{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:59:49Z","timestamp":1787504389197,"version":"build-2736575974"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In recent years, a range of cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors have been identified as significantly improving the survival of patients with hormone receptor-positive (HR+)\/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). As the use of CDK4\/6 inhibitors continues to increase, safety concerns have garnered increasing attention. Herein, this study analyzed adverse reactions in breast cancer patients receiving a CDK4\/6 inhibitor abemaciclib, with a focus on identifying risk factors for diarrhea and neutropenia through regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, a total of 216 BC patients receiving abemaciclib were enrolled. Follow-up observations towards the baseline and clinical characteristics in these patients were exhibited. The evaluation of adverse effects (AEs) in these patients was performed based on the clinical practice of abemaciclib whole-course management and the consensus on the management. Subsequently, we focused on the two most common adverse reactions during the use of abemaciclib, namely diarrhea and neutropenia. Furthermore, analysis of factors influencing incidence of diarrhea and neutropenia was executed using the univariate analysis and multivariate logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The safety profile of abemaciclib was manageable, and the drug was well tolerated by patients. The incidence of AEs was greater in the gastrointestinal system, blood and lymphatic system, liver system, renal system, muscular and skeletal systems, and skin and subcutaneous tissue systems. Age stratification and gastrointestinal diseases were independent risk factors for grade 2-3 diarrhea. Alternatively, the Eastern Cooperative Oncology Group (ECOG) score was a factor associated with the risk for grade 3-4 neutropenia. Baseline BMI classification, baseline white blood cell (WBC) count and baseline albumin (ALB) stratification were factors associated with protection against grade 3-4 neutropenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study retrospectively collected, processed, analyzed, and evaluated the safety profile of abemaciclib. Additionally, potential influencing factors associated with common adverse reactions including diarrhea and neutropenia were explored to provide a foundation for its rational clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1529980","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:10:43Z","timestamp":1750378243000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk factors for adverse reactions caused by abemaciclib in breast cancer therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Xianghua","family":"Quan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CaiHong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChuanZhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HuaiQin","family":"Cang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"B1","article-title":"Global cancer burden growing, amidst mounting need for services","volume":"45","year":"2024","journal-title":"Saudi Med J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3322\/caac.21777","article-title":"Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer","volume":"73","author":"Huppert","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02742","article-title":"FDA approval summary: abemaciclib with endocrine therapy for high-risk early breast cancer","volume":"40","author":"Royce","year":"2022","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.846","article-title":"Recent developments in the therapeutic landscape of advanced or metastatic hormone receptor-positive breast cancer","volume":"55","author":"Lee","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2024.01.002","article-title":"CDK4\/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety","volume":"50","author":"Wekking","year":"2023","journal-title":"Semin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1053\/j.seminoncol.2024.01.002","article-title":"NCCN guidelines\u00ae Insights: breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2225345","DOI":"10.1001\/jamanetworkopen.2022.25345","article-title":"Association of endocrine therapy initiation timeliness with adherence and continuation in low-income women with breast cancer","volume":"5","author":"Sood","year":"2022","journal-title":"JAMA network Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors","volume":"6","author":"Patnaik","year":"2016","journal-title":"Cancer Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13531","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16276","article-title":"Abemaciclib-associated diarrhea: an exploratory analysis of real-life data","volume":"43","author":"Gebbia","year":"2023","journal-title":"Anticancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1852934","article-title":"CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis","volume":"21","author":"Onesti","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.13-2-185","article-title":"Neutropenic sepsis: management and complications","volume":"13","author":"Clarke","year":"2013","journal-title":"Clin Med (Lond)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13811","article-title":"Evaluation of the association of polymorphisms with palbociclib-induced neutropenia: pharmacogenetic analysis of PALOMA-2\/-3","volume":"26","author":"Iwata","year":"2021","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2- metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.03.006","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920963925","article-title":"MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2- advanced breast cancer: the multinational randomized phase III study","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10549-022-06662-9","article-title":"nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR\u2009+\u2009, HER2- metastatic breast cancer","volume":"195","author":"Hamilton","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1923468","article-title":"Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer","volume":"37","author":"Cuyun Carter","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0734","article-title":"Intestinal toxicity in rats following administration of CDK4\/6 inhibitors is independent of primary pharmacology","volume":"18","author":"Thibault","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-169x.2004.00765.x","article-title":"All-trans retinoic acid enhances differentiation and influences permeability of intestinal Caco-2 cells under serum-free conditions","volume":"46","author":"Baltes","year":"2004","journal-title":"Dev Growth Differ"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and degree of CDK drug interactions predicts clinical performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.breast.2021.04.003","article-title":"Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib","volume":"58","author":"Modi","year":"2021","journal-title":"Breast"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines","volume":"29","author":"Bossi","year":"2018","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.5694\/mja13.00172","article-title":"Polypharmacy among inpatients aged 70 years or older in Australia","volume":"202","author":"Hubbard","year":"2015","journal-title":"Med J Aust"},{"key":"B28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40266-015-0318-1","article-title":"Age-related changes in hepatic function: an update on implications for drug therapy","volume":"32","author":"Tan","year":"2015","journal-title":"Drugs Aging"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/3614296","article-title":"Impact of CDK4\/6 inhibitors on aromatase inhibitor-associated musculoskeletal syndrome (AIMSS) in the adjuvant setting","volume":"2023","author":"Skafida","year":"2023","journal-title":"Breast J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23173","article-title":"Inflammation and cancer: an ancient link with novel potentials","volume":"121","author":"Hussain","year":"2007","journal-title":"Int J Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1038\/s41467-020-16559-0","article-title":"Quantifying CDK inhibitor selectivity in live cells","volume":"11","author":"Wells","year":"2020","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa116","article-title":"Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy","volume":"113","author":"Franzoi","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","article-title":"Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918793326","article-title":"Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer","volume":"10","author":"Thill","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-872648","article-title":"CDK6 coordinates JAK2 V617F mutant MPN via NF-\u03baB and apoptotic networks","volume":"133","author":"Uras","year":"2019","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601675","article-title":"Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C\/EBPalpha interaction","volume":"26","author":"Fujimoto","year":"2007","journal-title":"EMBO J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-06029-y","article-title":"Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials","volume":"186","author":"Goetz","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2023.24.6.1955","article-title":"Clinical management of potential toxicity of abemaciclib and approaches to ensure treatment continuation","volume":"24","author":"Takada","year":"2023","journal-title":"Asian Pac J Cancer Prev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12932","article-title":"Phase I study of palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, in Japanese patients","volume":"107","author":"Tamura","year":"2016","journal-title":"Cancer Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176350","article-title":"CDK4\/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions","volume":"21","author":"Roncato","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2073122","article-title":"Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting","volume":"38","author":"Price","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0559-8","article-title":"A population pharmacokinetic and pharmacodynamic analysis of abemaciclib in a phase I clinical trial in cancer patients","volume":"57","author":"Tate","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23614","article-title":"Plasma protein binding: From discovery to development","volume":"102","author":"Bohnert","year":"2013","journal-title":"J Pharm Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b22-00338","article-title":"The cyclin-dependent kinase 4\/6 inhibitor abemaciclib is tolerated better than palbociclib by advanced breast cancer patients with high serum albumin levels","volume":"45","author":"Nakatsukasa","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0928-4","article-title":"Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia","volume":"19","author":"Ahn","year":"2011","journal-title":"Support Care Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05842-x","article-title":"Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment","volume":"29","author":"Saito","year":"2021","journal-title":"Support Care Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw315","article-title":"Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study","volume":"27","author":"Furlanetto","year":"2016","journal-title":"Ann Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27515","article-title":"Obesity in pediatric patients with acute lymphoblastic leukemia increases the risk of adverse events during pre-maintenance chemotherapy","volume":"66","author":"Meenan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.571","article-title":"Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients","volume":"5","author":"Iwase","year":"2016","journal-title":"Cancer Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"9922","DOI":"10.1038\/s41598-021-89385-z","article-title":"Tumor apelin and obesity are associated with reduced neoadjuvant chemotherapy response in a cohort of breast cancer patients","volume":"11","author":"Gourgue","year":"2021","journal-title":"Sci Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2016.05.013","article-title":"Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients","volume":"32","author":"Karatas","year":"2017","journal-title":"Breast"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07400-z","article-title":"Risk factors associated with palbociclib-induced neutropenia in patients with metastatic breast cancer","volume":"30","author":"Lavery","year":"2022","journal-title":"Support Care Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00658.x","article-title":"Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia","volume":"76","author":"Herishanu","year":"2006","journal-title":"Eur J Haematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2014.194","article-title":"Obesity is associated with more activated neutrophils in African American male youth","volume":"39","author":"Xu","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007056","article-title":"Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy","volume":"4","author":"Mileti","year":"2009","journal-title":"PloS One"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.07.003","article-title":"Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)","volume":"71","author":"Masuda","year":"2023","journal-title":"Breast"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05261-5","article-title":"Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success","volume":"176","author":"Cazzaniga","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.3745","article-title":"Hepatitis B virus screening for patients with cancer before therapy: american society of clinical oncology provisional clinical opinion update","volume":"33","author":"Hwang","year":"2015","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/ijo.2014.194","article-title":"Obesity is associated with more activated neutrophils in African American male youth","volume":"39","author":"Xu","year":"2015","journal-title":"Int J Obes (Lond)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1529980\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:10:43Z","timestamp":1750378243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1529980\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":60,"alternative-id":["10.3389\/fonc.2025.1529980"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1529980","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"article-number":"1529980"}}